Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Eculizumab cessation in atypical hemolytic uremic syndrome.

Literature DB >> 28461395

Eculizumab cessation in atypical hemolytic uremic syndrome.

Samuel A Merrill¹, Zachary D Brittingham¹, Xuan Yuan¹, Alison R Moliterno¹, C John Sperati², Robert A Brodsky¹.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2017 PMID： 28461395 PMCID： PMC5520471 DOI： 10.1182/blood-2017-02-770214

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

× No keyword cloud information.

23 in total

1. Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome.

Authors: Shuju Feng; Stephen J Eyler; Yuzhou Zhang; Tara Maga; Carla M Nester; Michael H Kroll; Richard J Smith; Vahid Afshar-Kharghan
Journal: Blood Date: 2013-07-11 Impact factor: 22.113

2. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.

Authors: M Cugno; R Gualtierotti; I Possenti; S Testa; F Tel; S Griffini; E Grovetti; S Tedeschi; S Salardi; D Cresseri; P Messa; G Ardissino
Journal: J Thromb Haemost Date: 2014-07-16 Impact factor: 5.824

Review 3. Atypical hemolytic-uremic syndrome.

Authors: Marina Noris; Giuseppe Remuzzi
Journal: N Engl J Med Date: 2009-10-22 Impact factor: 91.245

4. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.

Authors: W R Bell; H G Braine; P M Ness; T S Kickler
Journal: N Engl J Med Date: 1991-08-08 Impact factor: 91.245

5. Modified Ham test for atypical hemolytic uremic syndrome.

Authors: Eleni Gavriilaki; Xuan Yuan; Zhaohui Ye; Alexander J Ambinder; Satish P Shanbhag; Michael B Streiff; Thomas S Kickler; Alison R Moliterno; C John Sperati; Robert A Brodsky
Journal: Blood Date: 2015-04-10 Impact factor: 22.113

6. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience.

Authors: Paul Coppo; Michael Schwarzinger; Marc Buffet; Alain Wynckel; Karine Clabault; Claire Presne; Pascale Poullin; Sandrine Malot; Philippe Vanhille; Elie Azoulay; Lionel Galicier; Virginie Lemiale; Jean-Paul Mira; Christophe Ridel; Eric Rondeau; Jacques Pourrat; Stéphane Girault; Dominique Bordessoule; Samir Saheb; Michel Ramakers; Mohamed Hamidou; Jean-Paul Vernant; Bertrand Guidet; Martine Wolf; Agnès Veyradier
Journal: PLoS One Date: 2010-04-23 Impact factor: 3.240

7. Opportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria.

Authors: Doug Coyle; Matthew C Cheung; Gerald A Evans
Journal: Med Decis Making Date: 2014-07-02 Impact factor: 2.583

8. ADAMTS13 gene mutations in children with hemolytic uremic syndrome.

Authors: Hyoung Soo Choi; Hae Il Cheong; Nam Keun Kim; Doyeun Oh; Hye Won Park
Journal: Yonsei Med J Date: 2011-05 Impact factor: 2.759

9. Analysis of rare variants in the CFH gene in patients with the cuticular drusen subtype of age-related macular degeneration.

Authors: Maheswara R Duvvari; Nicole T M Saksens; Johannes P H van de Ven; Yvonne de Jong-Hesse; Tina Schick; Willy M Nillesen; Sascha Fauser; Lies H Hoefsloot; Carel B Hoyng; Eiko K de Jong; Anneke I den Hollander
Journal: Mol Vis Date: 2015-03-15 Impact factor: 2.367

10. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome.

Authors: Peter F Zipfel; Matthew Edey; Stefan Heinen; Mihály Józsi; Heiko Richter; Joachim Misselwitz; Bernd Hoppe; Danny Routledge; Lisa Strain; Anne E Hughes; Judith A Goodship; Christoph Licht; Timothy H J Goodship; Christine Skerka
Journal: PLoS Genet Date: 2007-02-01 Impact factor: 5.917

22 in total

Review 1. Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria.

Authors: Samuel A Merrill; Robert A Brodsky
Journal: Hematology Am Soc Hematol Educ Program Date: 2018-11-30

2. Eculizumab and aHUS: to stop or not.

Authors: Robert A Brodsky
Journal: Blood Date: 2021-05-06 Impact factor: 22.113

Review 3. Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications.

Authors: Shruti Chaturvedi; Evan M Braunstein; Robert A Brodsky
Journal: J Thromb Haemost Date: 2021-02-10 Impact factor: 5.824

4. Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.

Authors: Julien Zuber; Marie Frimat; Sophie Caillard; Nassim Kamar; Philippe Gatault; Florent Petitprez; Lionel Couzi; Noemie Jourde-Chiche; Valérie Chatelet; Raphael Gaisne; Dominique Bertrand; Jamal Bamoulid; Magali Louis; Rebecca Sberro Soussan; David Navarro; Pierre-Francois Westeel; Luc Frimat; Charlotte Colosio; Antoine Thierry; Joseph Rivalan; Laetitia Albano; Nadia Arzouk; Emilie Cornec-Le Gall; Guillaume Claisse; Michelle Elias; Khalil El Karoui; Sophie Chauvet; Jean-Philippe Coindre; Jean-Philippe Rerolle; Leila Tricot; Johnny Sayegh; Cyril Garrouste; Christophe Charasse; Yahsou Delmas; Ziad Massy; Maryvonne Hourmant; Aude Servais; Chantal Loirat; Fadi Fakhouri; Claire Pouteil-Noble; Marie-Noelle Peraldi; Christophe Legendre; Eric Rondeau; Moglie Le Quintrec; Véronique Frémeaux-Bacchi
Journal: J Am Soc Nephrol Date: 2019-10-01 Impact factor: 10.121

Review 5. Complementopathies and precision medicine.

Authors: Eleni Gavriilaki; Robert A Brodsky
Journal: J Clin Invest Date: 2020-05-01 Impact factor: 14.808

6. Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome.

Authors: Shruti Chaturvedi; Noor Dhaliwal; Sarah Hussain; Kathryn Dane; Harshvardhan Upreti; Evan M Braunstein; Xuan Yuan; C John Sperati; Alison R Moliterno; Robert A Brodsky
Journal: Blood Adv Date: 2021-03-09